Open AccessSurfactant in SARS-CoV-2 - a therapeutic option based on underlying lung cell damage?
Author(s) -
Maristella de Araújo Carvalho Sousa,
Gabriela Correia Matos de Oliveira,
Luís Jesuino de Oliveira Andrade
Publication year - 2020
Publication title -
revista de ciências médicas e biológicas
Language(s) - English
Resource type - Journals
eISSN - 2236-5222
pISSN - 1677-5090
DOI - 10.9771/cmbio.v19i4.37015
Subject(s) - pulmonary surfactant , respiratory distress , lung , respiratory system , medicine , neonatal respiratory distress syndrome , covid-19 , secretion , immunology , disease , biology , anesthesia , infectious disease (medical specialty) , pregnancy , biochemistry , genetics , gestational age
: the severe acute respiratory syndrome – coronavirus 2 (SARS Cov-2), leads to a diffuse alveolar deterioration due infection of type II pneumocytes. The type II pneumocytes are involved in synthesis and secretion of pulmonary surfactant in pulmonary alveoli. Objective : the purpose of this study is to discuss the indication of surfactant replacement as a potential adjunctive treatment modality for SARS CoV-2, similarly treatment to neonatal respiratory distress syndrome. Methodology : we argue that SARS can be triggered by surfactant deficiency secondary to production deficiency determined by type 2 pneumocyte injuries. In this sense, we carried out a bibliographic review. Conclusion : thus, the replacement of human surfactant could be a potential treatment modality for SARS CoV-2, in the same way that it is indicated for the treatment of neonatal respiratory distress syndrome